DC
MIRM icon

Davenport & Co’s Mirum Pharmaceuticals MIRM Stock Holding History

Davenport & Co’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$328K Buy
2,805
+155
+6% +$15.6K ﹤0.01% 1163
2026
Q1 		$245K Buy
+2,650
New +$249K ﹤0.01% 1207

Other funds holding MIRM

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
SOAM
SBI Okasan Asset Management Tokyo, Japan $3.04B AUM
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Davenport & Co's MIRM Position: Q2 2026 in Review

Davenport & Co increased its Mirum Pharmaceuticals (MIRM) stake by 5.8% in Q2 2026, buying an estimated $15.6K and bringing the position to 2,805 shares worth $328K. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Davenport & Co first reported a position in MIRM in Q1 2026 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Davenport & Co held 2,805 shares of Mirum Pharmaceuticals worth $328K as of Q2 2026.
  • Davenport & Co bought 155 Mirum Pharmaceuticals shares in Q2 2026, an estimated $15.6K.
  • Mirum Pharmaceuticals made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1163 holding.
  • Davenport & Co first reported a position in Mirum Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.